Targeting MET for glioma therapy

Neurosurgical Focus

Volumn 37, Issue 6, 2014, Pages

  Awad, Ahmed J ^a   Burns, Terry C ^b   Zhang, Ying ^a   Abounader, Roger ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma multiforme; Hepatocyte growth factor; MET

Indexed keywords

MET PROTEIN, HUMAN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

BRAIN NEOPLASMS; DRUG EFFECTS; GLIOMA; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

BRAIN NEOPLASMS; GLIOMA; HEPATOCYTE GROWTH FACTOR; HUMANS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84916883583     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2014.9.FOCUS14520     Document Type: Article

References (69)

1. Abounader R: Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Rev Anticancer Ther 9:235-245, 2009
2. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, et al: In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 16:108-110, 2002
3. Abounader R, Laterra J: Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7:436-451, 2005
4. Abounader R, Ranganathan S, Kim BY, Nichols C, Laterra J: Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. J Neurochem 76:1497-1508, 2001
5. Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, et al: Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/ hepatocyte growth factor and c-met expression. J Natl Cancer Inst 91:1548-1556, 1999
6. Affronti ML, Desjardins A, Friedman HS, Peters KB, Herndon JE II, McSherry F, et al: Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG). J Clin Oncol 30 Suppl:2074, 2012 (Abstract)
7. Arrieta O, Garcia E, Guevara P, Garcia-Navarrete R, Ondarza R, Rembao D, et al: Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer 94:3210-3218, 2002
8. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925, 2003
9. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 411:355-365, 2001
10. Boccaccio C, Andò M, Tamagnone L, Bardelli A, Michieli P, Battistini C, et al: Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391:285-288, 1998
11. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802-804, 1991
12. Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, Rosen EM, et al: Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 60:4277-4283, 2000
13. Brockmann MA, Papadimitriou A, Brandt M, Fillbrandt R, Westphal M, Lamszus K: Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res 9:4578-4585, 2003
14. Brockmann MA, Ulbricht U, Grüner K, Fillbrandt R, Westphal M, Lamszus K: Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 52:1391-1399, 2003
15. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
16. Chu SH, Ma YB, Feng DF, Zhang H, Qiu JH, Zhu ZA: c-Met antisense oligodeoxynucleotides increase sensitivity of human glioma cells to paclitaxel. Oncol Rep 24:189-194, 2010
17. Comoglio PM, Giordano S, Trusolino L: Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504-516, 2008
18. De Groot JF, Prados M, Urquhart T, Robertson S, Yaron Y, Sorensen AG, et al: A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. ASCO Meeting Abstracts 27:2047, 2009
19. Fan S, Ma YX, Gao M, Yuan RQ, Meng Q, Goldberg ID, et al: The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol Cell Biol 21:4968-4984, 2001
20. Fan S, Meng Q, Laterra JJ, Rosen EM: Ras effector pathways modulate scatter factor-stimulated NF-kappaB signaling and protection against DNA damage. Oncogene 26:4774-4796, 2007
21. Fuller GN, Ribalta T: Brain tumors: an overview of current histopathologic classifications, in Winn HR (ed): Youmans Neurological Surgery, ed 6. Philadelphia: Elsevier/Saunders, 2011, Vol 2, pp 1077-1086
22. Gherardi E, Youles ME, Miguel RN, Blundell TL, Iamele L, Gough J, et al: Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 100:12039-12044, 2003
23. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM: Tyrosine kinase receptor indistinguishable from the cmet protein. Nature 339:155-156, 1989
24. Gude NA, Emmanuel G, Wu W, Cottage CT, Fischer K, Quijada P, et al: Activation of Notch-mediated protective signaling in the myocardium. Circ Res 102:1025-1035, 2008
25. Guessous F, Zhang Y, diPierro C, Marcinkiewicz L, Sarkaria J, Schiff D, et al: An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem 10:28-35, 2010
26. Hamasuna R, Kataoka H, Moriyama T, Itoh H, Seiki M, Koono M: Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP. Int J Cancer 82:274-281, 1999
27. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, et al: Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 19:1773-1783, 2013
28. Johnson DR, O'Neill BP: Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 107:359-364, 2012
29. Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Gu Kang B, et al: MET signaling regulates glioblastoma stem cells. Cancer Res 72:3828-3838, 2012
30. Kim KH, Seol HJ, Kim EH, Rheey J, Jin HJ, Lee Y, et al: Wnt/b-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol 15:161-171, 2013
31. Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, et al: Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 12:1292-1298, 2006
32. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, et al: Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57:5391-5398, 1997
33. Kunkel P, Müller S, Schirmacher P, Stavrou D, Fillbrandt R, Westphal M, et al: Expression and localization of scatter factor/ hepatocyte growth factor in human astrocytomas. Neuro Oncol 3:82-88, 2001
34. Lafleur MA, Handsley MM, Knäuper V, Murphy G, Edwards DR: Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci 115:3427-3438, 2002
35. Laisney JA, Mueller TD, Schartl M, Meierjohann S: Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops. Oncogene 32:2403-2411, 2013
36. Lal B, Xia S, Abounader R, Laterra J: Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res 11:4479-4486, 2005
37. Lamszus K, Laterra J, Westphal M, Rosen EM: Scatter factor/ hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci 17:517-530, 1999
38. Lamszus K, Schmidt NO, Jin L, Laterra J, Zagzag D, Way D, et al: Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int J Cancer 75:19-28, 1998
39. Laterra J, Nam M, Rosen E, Rao JS, Lamszus K, Goldberg ID, et al: Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 76:565-577, 1997
40. Li Y, Guessous F, DiPierro C, Zhang Y, Mudrick T, Fuller L, et al: Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Mol Cancer Ther 8:376-385, 2009
41. Li Y, Guessous F, Johnson EB, Eberhart CG, Li XN, Shu Q, et al: Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Invest 88:98-111, 2008
42. Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, et al: The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 65:9355-9362, 2005
43. Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, et al: c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A 108:9951-9956, 2011
44. Lock LS, Royal I, Naujokas MA, Park M: Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases. J Biol Chem 275:31536-31545, 2000
45. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA: Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729-3735, 2002
46. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al: A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12:6144-6152, 2006
47. Martínez-Rumayor A, Arrieta O, Guevara P, Escobar E, Rembao D, Salina C, et al: Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. Cancer Lett 213:117-124, 2004
48. Miyazawa K, Shimomura T, Kitamura A, Kondo J, Morimoto Y, Kitamura N: Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem 268:10024-10028, 1993
49. Monga SP, Mars WM, Pediaditakis P, Bell A, Mulé K, Bowen WC, et al: Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 62:2064-2071, 2002
50. Moriyama T, Kataoka H, Hamasuna R, Yoshida E, Sameshima T, Iseda T, et al: Simultaneous up-regulation of urokinasetype plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells. Clin Exp Metastasis 17:873-879, 1999
51. Moriyama T, Kataoka H, Kawano H, Yokogami K, Nakano S, Goya T, et al: Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans. Cancer Lett 124:149-155, 1998
52. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, Matsumoto K, et al: Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension 37:581-586, 2001
53. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al: Molecular cloning and expression of human hepatocyte growth factor. Nature 342:440-443, 1989
54. Ohgaki H: Epidemiology of brain tumors. Methods Mol Biol 472:323-342, 2009
55. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, et al: A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77:261-271, 1994
56. Rath P, Lal B, Ajala O, Li Y, Xia S, Kim J, et al: In vivo c-Met pathway inhibition depletes human glioma xenografts of tumor-propagating stem-like cells. Transl Oncol 6:104-111, 2013
57. Reznik TE, Sang Y, Ma Y, Abounader R, Rosen EM, Xia S, et al: Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 6:139-150, 2008
58. Rosen EM, Laterra J, Joseph A, Jin L, Fuchs A, Way D, et al: Scatter factor expression and regulation in human glial tumors. Int J Cancer 67:248-255, 1996
59. Schmidt NO, Westphal M, Hagel C, Ergün S, Stavrou D, Rosen EM, et al: Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 84:10-18, 1999
60. Seki T, Hagiya M, Shimonishi M, Nakamura T, Shimizu S: Organization of the human hepatocyte growth factor-encoding gene. Gene 102:213-219, 1991
61. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al: Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290, 2007
62. Vlahovic G, Crawford J: Activation of tyrosine kinases in cancer. Oncologist 8:531-538, 2003
63. Walter KA, Hossain MA, Luddy C, Goel N, Reznik TE, Laterra J: Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription. Mol Cell Biol 22:2703-2715, 2002
64. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W: Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384:173-176, 1996
65. Welch WC, Kornblith PL, Michalopoulos GK, Petersen BE, Beedle A, Gollin SM, et al: Hepatocyte growth factor (HGF) and receptor (c-met) in normal and malignant astrocytic cells. Anticancer Res 19 (3A):1635-1640, 1999
66. Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, et al: A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 13:437-446, 2011
67. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR: Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A 98:247-252, 2001
68. Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, et al: Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A 109:570-575, 2012
69. Zhang Y, Farenholtz KE, Yang Y, Guessous F, Dipierro CG, Calvert VS, et al: Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition. Clin Cancer Res 19:1433-1444, 2013